Detalles de la búsqueda
1.
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).
Am J Respir Crit Care Med
; 207(2): 138-149, 2023 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972987
2.
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 378(26): 2465-2474, 2018 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29949494
3.
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Cancer
; 123(12): 2303-2311, 2017 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28171710
4.
Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med
; 371(5): 424-33, 2014 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-24881730
5.
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
J Urol
; 198(6): 1324-1332, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28736322
6.
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.
Health Qual Life Outcomes
; 15(1): 130, 2017 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28645287
7.
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Lancet Oncol
; 17(2): 153-163, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26774508
8.
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Lancet Oncol
; 16(5): 509-21, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25888263
9.
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Lancet Oncol
; 15(6): 592-600, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24739897
10.
Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
Value Health
; 17(2): 238-44, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24636382
11.
Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate-Severe Atopic Dermatitis.
J Clin Med
; 11(23)2022 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36498818
12.
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Invest New Drugs
; 29(1): 118-25, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19763400
13.
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
BJU Int
; 106(7): 966-73, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20840318
14.
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Eur Urol Oncol
; 2(6): 677-684, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31274110
15.
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
JAMA Oncol
; 4(5): 694-701, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29522174
16.
Combined androgen blockade in advanced prostate cancer: looking back to move forward.
Clin Genitourin Cancer
; 5(6): 371-8, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17956709
17.
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.
Target Oncol
; 12(1): 111-121, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27981431
18.
The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
Eur J Cancer
; 87: 21-29, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29096157
19.
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Clin Genitourin Cancer
; 15(5): 610-617.e3, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28344102
20.
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
J Clin Oncol
; 34(18): 2098-106, 2016 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26811535